Inventor · disambiguated record
Matthew Seavey
Also filed as: SEAVEY MATTHEW · SEAVEY MATTHEW M
11 granted patents·8 pending applications·93 citations·filing 2008–2022
90Inventor score
Top patents by PatentIndex Score
19 records- 0194US9981024B2Compositions comprising angiogenic factors and methods of use thereofUNIV PENNSYLVANIA·Filed 2016·Granted May 29, 2018·7 cites·18 claims
- 0294US9919038B2Compositions comprising angiogenic factors and methods of use thereofUNIV PENNSYLVANIA·Filed 2016·Granted Mar 20, 2018·7 cites·16 claims
- 0393US8268326B2Compositions comprising HMW-MAA and fragments thereof, and methods of use thereofPATERSON YVONNE·Filed 2008·Granted Sep 18, 2012·16 cites·7 claims
- 0490US9408898B2Compositions comprising angiogenic factors and methods of use thereofUNIV PENNSYLVANIA·Filed 2014·Granted Aug 9, 2016·10 cites·28 claims
- 0590US9017660B2Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumorsSHAHABI VAFA·Filed 2011·Granted Apr 28, 2015·22 cites·61 claims
- 0687US9084747B2Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumorsSHAHABI VAFA·Filed 2010·Granted Jul 21, 2015·16 cites·25 claims
- 0786US8778329B2Compositions comprising angiogenic factors and methods of use thereofSEAVEY MATTHEW·Filed 2010·Granted Jul 15, 2014·12 cites·15 claims
- 0871US10695410B2Compositions comprising angiogenic factors and methods of use thereofUNIV PENNSYLVANIA·Filed 2018·Granted Jun 30, 2020·0 cites·20 claims
- 0970US9340559B2Proteasome inhibitor delanzomib for use in the treatment of lupusRUGGERI BRUCE A·Filed 2012·Granted May 17, 2016·3 cites·10 claims
- 1061US2015366955A9Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2014·Application pending·0 cites
- 1154US2024368278A1Generation and characterization of novel tim-4 binding agentsHEAT BIOLOGICS INC·Filed 2022·Application pending·0 cites
- 1251US2022298252A1Methods of treating cancer using tnfrsf25 antibodiesPELICAN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1350US2015297702A1Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2015·Application pending·0 cites
- 1447US9034876B2Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivativeCEPHALON INC·Filed 2013·Granted May 19, 2015·0 cites·15 claims
- 1547US9023853B2Janus kinase 2 (JAK2) inhibitor for the treatment of lupusCEPHALON INC·Filed 2013·Granted May 5, 2015·0 cites·17 claims
- 1647US2016361401A1Compositions and methods for the treatment of her2/neu over-expressing tumorsADVAXIS INC·Filed 2015·Application pending·0 cites
- 1746US2022340672A1Tnfrsf25-mediated treatments of immune diseases and disordersPELICAN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1843US2016303116A1Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a] pyridine derivativeCEPHALON INC·Filed 2014·Application pending·0 cites
- 1938US2011223187A1Live listeria-based vaccines for central nervous system therapySHAHABI VAFA·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →